Patents by Inventor Guy Lalonde
Guy Lalonde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9155797Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: GrantFiled: July 22, 2014Date of Patent: October 13, 2015Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Publication number: 20140329895Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: ApplicationFiled: July 22, 2014Publication date: November 6, 2014Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Patent number: 8829043Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: GrantFiled: February 6, 2009Date of Patent: September 9, 2014Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Patent number: 8729030Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: November 12, 2010Date of Patent: May 20, 2014Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
-
Publication number: 20130244939Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: November 1, 2012Publication date: September 19, 2013Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20130012685Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: July 3, 2012Publication date: January 10, 2013Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
-
Patent number: 8304391Abstract: Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: March 17, 2009Date of Patent: November 6, 2012Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20120231025Abstract: This invention provides a family of immunogenic compositions and vaccines, each containing a target antigen or antigen mixture, and an oligopeptide adjuvant, exemplified by the tripeptide Ile-Glu-Trp. The adjuvant has a low side effect profile, and may be especially effective in generating a rapid and specific Th1 or cellular immune response where the antigen is poorly immunogenic, or the patient is elderly or immunocompromised. In some circumstances, effectiveness of the vaccine can be substantially enhanced by administering follow-on injections of the tripeptide alone. The vaccine has been used to generate an enhanced response to multiple strains of influenza simultaneously, and is suitable for preventing or treating other infectious and disease conditions.Type: ApplicationFiled: August 10, 2010Publication date: September 13, 2012Inventors: David Sahner, Guy LaLonde
-
Publication number: 20120157660Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: August 18, 2010Publication date: June 21, 2012Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
-
Publication number: 20120022063Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: ApplicationFiled: February 6, 2009Publication date: January 26, 2012Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Publication number: 20110282029Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: December 10, 2010Publication date: November 17, 2011Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
-
Publication number: 20110245176Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: November 12, 2010Publication date: October 6, 2011Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Patent number: 7855175Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: July 11, 2008Date of Patent: December 21, 2010Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
-
Publication number: 20090227508Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: March 17, 2009Publication date: September 10, 2009Applicant: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Patent number: 7528104Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: May 12, 2004Date of Patent: May 5, 2009Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20090048166Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: July 11, 2008Publication date: February 19, 2009Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20090005292Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: November 11, 2005Publication date: January 1, 2009Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
-
Patent number: 7414105Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: October 27, 2005Date of Patent: August 19, 2008Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20080108564Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: April 13, 2007Publication date: May 8, 2008Applicant: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
-
Publication number: 20070027074Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: May 12, 2004Publication date: February 1, 2007Applicant: Affymax, Inc.Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede